Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

doi:10.1158/1078-0432.CCR-25-4796

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2026

Vujanovic Lazar, Torres-Saavedra Pedro, Tu Fei, Uppaluri Ravindra, Yao Min, Chen Josephine, Jordan Richard, Geiger Jessica L, Jujjavarapu Srinivas, Chakravarti Arnab, Phan Minh, Siddiqui Farzan, Kulkarni Aditi, Upadhyay Pragati, Isett Brian Robert, Sica Gabriel L, Reeder Carly, Bao Riyue, Chen Jie, Joy Marion, Freeman Tanner, Harris Jonathan, Le Quynh-Thu, Bauman Julie E, Ferris Robert L

Abstract excerpt

PURPOSE: Patients with pathologically high-risk, human papillomavirus-negative squamous cell carcinoma of the head and neck (HNSCC) recur frequently despite adjuvant cisplatin radiotherapy (CRT). As CRT can upregulate PD-1/L1 immune checkpoints, adding pembrolizumab may reverse treatment-induced immunosuppression. NRG-HN003 was a phase I trial assessing the safety and recommended phase II schedule of adjuvant...

Read the complete abstract on PubMed

Topics

Adult
Aged
Female

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Humans

Male

Middle Aged

Antibodies, Monoclonal, Humanized

B7-H1 Antigen

Biomarkers, Tumor

Chemoradiotherapy

Head and Neck Neoplasms

Mutation

Prognosis

Squamous Cell Carcinoma of Head and Neck

Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 42347893
DOI: 10.1158/1078-0432.CCR-25-4796
PMCID: PMC13308182

Genes

TP53
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.PMID 42347893Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

Integrated Histopathology–Transcriptomic Biomarker Enhances Survival Prediction in HNSCC Patients Treated with ImmunotherapySemantic proximity Read ↗

The Single-Cell Landscape of Peripheral and Tumor-infiltrating Immune Cells in HPV- HNSCCSemantic proximity Read ↗

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Myeloid-Mediated Immunoregulation Across Squamous Cell CarcinomasSemantic proximity Read ↗

Mapping the Spatial Proteome of Head and Neck Tumors: Key Immune Mediators and Metabolic Determinants in the Tumor MicroenvironmentSemantic proximity Read ↗

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.Semantic proximity Read ↗

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.Semantic proximity Read ↗

A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD-1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.